NASDAQ:VBIV

VBI Vaccines Competitors

$2.74
-0.08 (-2.84 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.68
Now: $2.74
$2.85
50-Day Range
$2.86
MA: $3.26
$3.69
52-Week Range
$0.91
Now: $2.74
$6.93
Volume3.49 million shs
Average Volume6.80 million shs
Market Capitalization$695.97 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14

Competitors

VBI Vaccines (NASDAQ:VBIV) Vs. TARO, OPK, CORT, ITCI, DCPH, and RCKT

Should you be buying VBIV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to VBI Vaccines, including Taro Pharmaceutical Industries (TARO), OPKO Health (OPK), Corcept Therapeutics (CORT), Intra-Cellular Therapies (ITCI), Deciphera Pharmaceuticals (DCPH), and Rocket Pharmaceuticals (RCKT).

VBI Vaccines (NASDAQ:VBIV) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Volatility and Risk

VBI Vaccines has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Profitability

This table compares VBI Vaccines and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VBI Vaccines-2,837.73%-36.69%-28.29%
Taro Pharmaceutical Industries-45.94%10.36%8.38%

Analyst Recommendations

This is a summary of current ratings for VBI Vaccines and Taro Pharmaceutical Industries, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VBI Vaccines00313.25
Taro Pharmaceutical Industries00103.00

VBI Vaccines presently has a consensus target price of $7.00, suggesting a potential upside of 155.47%. Taro Pharmaceutical Industries has a consensus target price of $81.00, suggesting a potential upside of 11.59%. Given VBI Vaccines' stronger consensus rating and higher probable upside, research analysts plainly believe VBI Vaccines is more favorable than Taro Pharmaceutical Industries.

Earnings and Valuation

This table compares VBI Vaccines and Taro Pharmaceutical Industries' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VBI Vaccines$2.22 million313.50$-54,810,000.00($0.46)-5.96
Taro Pharmaceutical Industries$644.77 million4.31$244.24 million$6.3511.43

Taro Pharmaceutical Industries has higher revenue and earnings than VBI Vaccines. VBI Vaccines is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

52.1% of VBI Vaccines shares are owned by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are owned by institutional investors. 10.5% of VBI Vaccines shares are owned by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Taro Pharmaceutical Industries beats VBI Vaccines on 8 of the 15 factors compared between the two stocks.

OPKO Health (NASDAQ:OPK) and VBI Vaccines (NASDAQ:VBIV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

OPKO Health has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for OPKO Health and VBI Vaccines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OPKO Health00203.00
VBI Vaccines00313.25

OPKO Health currently has a consensus price target of $9.00, indicating a potential upside of 121.67%. VBI Vaccines has a consensus price target of $7.00, indicating a potential upside of 155.47%. Given VBI Vaccines' stronger consensus rating and higher probable upside, analysts clearly believe VBI Vaccines is more favorable than OPKO Health.

Earnings & Valuation

This table compares OPKO Health and VBI Vaccines' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OPKO Health$901.90 million3.02$-314,920,000.00($0.41)-9.90
VBI Vaccines$2.22 million313.50$-54,810,000.00($0.46)-5.96

VBI Vaccines has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

28.5% of OPKO Health shares are owned by institutional investors. Comparatively, 52.1% of VBI Vaccines shares are owned by institutional investors. 40.9% of OPKO Health shares are owned by company insiders. Comparatively, 10.5% of VBI Vaccines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares OPKO Health and VBI Vaccines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OPKO Health-9.79%-2.61%-1.80%
VBI Vaccines-2,837.73%-36.69%-28.29%

Summary

VBI Vaccines beats OPKO Health on 9 of the 15 factors compared between the two stocks.

VBI Vaccines (NASDAQ:VBIV) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for VBI Vaccines and Corcept Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VBI Vaccines00313.25
Corcept Therapeutics01102.50

VBI Vaccines currently has a consensus target price of $7.00, suggesting a potential upside of 155.47%. Corcept Therapeutics has a consensus target price of $24.00, suggesting a potential upside of 7.00%. Given VBI Vaccines' stronger consensus rating and higher probable upside, research analysts plainly believe VBI Vaccines is more favorable than Corcept Therapeutics.

Profitability

This table compares VBI Vaccines and Corcept Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VBI Vaccines-2,837.73%-36.69%-28.29%
Corcept Therapeutics30.73%25.38%23.16%

Insider & Institutional Ownership

52.1% of VBI Vaccines shares are owned by institutional investors. Comparatively, 75.4% of Corcept Therapeutics shares are owned by institutional investors. 10.5% of VBI Vaccines shares are owned by insiders. Comparatively, 16.4% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares VBI Vaccines and Corcept Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VBI Vaccines$2.22 million313.50$-54,810,000.00($0.46)-5.96
Corcept Therapeutics$306.49 million8.59$94.18 million$0.7729.13

Corcept Therapeutics has higher revenue and earnings than VBI Vaccines. VBI Vaccines is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

VBI Vaccines has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Summary

Corcept Therapeutics beats VBI Vaccines on 9 of the 15 factors compared between the two stocks.

Intra-Cellular Therapies (NASDAQ:ITCI) and VBI Vaccines (NASDAQ:VBIV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Institutional and Insider Ownership

79.1% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 52.1% of VBI Vaccines shares are held by institutional investors. 18.2% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 10.5% of VBI Vaccines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Intra-Cellular Therapies and VBI Vaccines, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intra-Cellular Therapies00703.00
VBI Vaccines00313.25

Intra-Cellular Therapies currently has a consensus price target of $47.4286, suggesting a potential upside of 49.57%. VBI Vaccines has a consensus price target of $7.00, suggesting a potential upside of 155.47%. Given VBI Vaccines' stronger consensus rating and higher probable upside, analysts clearly believe VBI Vaccines is more favorable than Intra-Cellular Therapies.

Earnings & Valuation

This table compares Intra-Cellular Therapies and VBI Vaccines' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intra-Cellular Therapies$60,000.0042,764.63$-147,720,000.00($2.68)-11.83
VBI Vaccines$2.22 million313.50$-54,810,000.00($0.46)-5.96

VBI Vaccines has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Intra-Cellular Therapies and VBI Vaccines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intra-Cellular Therapies-1,985.32%-48.27%-42.56%
VBI Vaccines-2,837.73%-36.69%-28.29%

Risk and Volatility

Intra-Cellular Therapies has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500.

Summary

VBI Vaccines beats Intra-Cellular Therapies on 9 of the 15 factors compared between the two stocks.

Deciphera Pharmaceuticals (NASDAQ:DCPH) and VBI Vaccines (NASDAQ:VBIV) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares Deciphera Pharmaceuticals and VBI Vaccines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Deciphera PharmaceuticalsN/A-45.02%-40.12%
VBI Vaccines-2,837.73%-36.69%-28.29%

Risk and Volatility

Deciphera Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500.

Valuation & Earnings

This table compares Deciphera Pharmaceuticals and VBI Vaccines' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Deciphera Pharmaceuticals$25 million101.54$-192,260,000.00($4.48)-9.83
VBI Vaccines$2.22 million313.50$-54,810,000.00($0.46)-5.96

VBI Vaccines has lower revenue, but higher earnings than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

73.6% of Deciphera Pharmaceuticals shares are held by institutional investors. Comparatively, 52.1% of VBI Vaccines shares are held by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of VBI Vaccines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Deciphera Pharmaceuticals and VBI Vaccines, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Deciphera Pharmaceuticals03702.70
VBI Vaccines00313.25

Deciphera Pharmaceuticals currently has a consensus target price of $70.30, indicating a potential upside of 59.59%. VBI Vaccines has a consensus target price of $7.00, indicating a potential upside of 155.47%. Given VBI Vaccines' stronger consensus rating and higher probable upside, analysts plainly believe VBI Vaccines is more favorable than Deciphera Pharmaceuticals.

Summary

VBI Vaccines beats Deciphera Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and VBI Vaccines (NASDAQ:VBIV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Insider & Institutional Ownership

52.1% of VBI Vaccines shares are held by institutional investors. 41.4% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 10.5% of VBI Vaccines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and VBI Vaccines' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-25.93
VBI Vaccines$2.22 million313.50$-54,810,000.00($0.46)-5.96

VBI Vaccines has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rocket Pharmaceuticals and VBI Vaccines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
VBI Vaccines-2,837.73%-36.69%-28.29%

Analyst Ratings

This is a summary of current ratings and price targets for Rocket Pharmaceuticals and VBI Vaccines, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011302.93
VBI Vaccines00313.25

Rocket Pharmaceuticals currently has a consensus target price of $59.1818, suggesting a potential upside of 44.45%. VBI Vaccines has a consensus target price of $7.00, suggesting a potential upside of 155.47%. Given VBI Vaccines' stronger consensus rating and higher probable upside, analysts clearly believe VBI Vaccines is more favorable than Rocket Pharmaceuticals.

Volatility & Risk

Rocket Pharmaceuticals has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500.

Summary

VBI Vaccines beats Rocket Pharmaceuticals on 9 of the 14 factors compared between the two stocks.


VBI Vaccines Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.59-0.3%$2.78 billion$644.77 million-10.36
OPKO Health logo
OPK
OPKO Health
1.9$4.06-3.0%$2.72 billion$901.90 million-22.55
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.43-1.1%$2.63 billion$306.49 million25.20
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.71-0.1%$2.57 billion$60,000.00-9.85News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.05-0.5%$2.54 billion$25 million-8.81
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.97-3.8%$2.53 billionN/A-22.51
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$39.97-2.0%$2.48 billion$2.11 million-8.65
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.29-1.1%$2.46 billion$182.24 million-8.08
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.90-5.9%$2.41 billion$120.28 million-146.36
Cryoport logo
CYRX
Cryoport
1.9$51.64-1.3%$2.36 billion$33.94 million-89.03Insider Selling
Xencor logo
XNCR
Xencor
1.2$39.59-2.2%$2.35 billion$156.70 million-28.28News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.95-10.0%$2.33 billionN/A0.00
Amarin logo
AMRN
Amarin
1.6$5.84-1.5%$2.30 billion$429.76 million-116.78
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$30.49-2.7%$2.22 billion$15 million-15.96
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.30-1.2%$2.21 billion$963.01 million13.76News Coverage
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.91-0.8%$2.01 billion$410,000.00-6.07
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.18-0.3%$2.00 billion$23.90 million-16.26Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$51.89-2.1%$1.94 billionN/A-19.29
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$62.10-10.3%$1.91 billionN/A-26.43Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.62-0.2%$1.89 billionN/A-17.56
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$24.53-3.7%$1.88 billion$103.54 million-18.44
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.0%$1.88 billionN/A-10.57
MORF
Morphic
1.1$57.73-2.8%$1.87 billion$16.98 million-37.01Insider Selling
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.16-2.1%$1.85 billion$34.51 million-17.23
FibroGen logo
FGEN
FibroGen
1.8$19.89-6.6%$1.82 billion$256.58 million-7.62Analyst Revision
MacroGenics logo
MGNX
MacroGenics
1.4$30.07-3.6%$1.80 billion$64.19 million-9.61
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00News Coverage
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.97-0.1%$1.77 billion$14.87 million-14.17
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.77-3.3%$1.73 billion$1.63 billion14.07News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$23.85-1.3%$1.71 billion$26.87 million-12.49Insider Selling
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$40.42-7.4%$1.66 billionN/A0.00Analyst Report
High Trading Volume
News Coverage
Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$17.18-5.6%$1.65 billionN/A-6.11News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.16-0.3%$1.64 billion$428.41 million14.72
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.72-1.4%$1.61 billionN/A0.00
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.64-1.3%$1.61 billion$320,000.00-8.60Analyst Report
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$22.76-5.4%$1.57 billion$2.34 million-9.64
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.70-7.8%$1.52 billionN/A0.00Insider Selling
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$27.97-1.2%$1.50 billion$392.76 million11.61
uniQure logo
QURE
uniQure
1.7$33.14-1.8%$1.49 billion$7.28 million-8.79
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.29-1.9%$1.49 billion$145.97 million-6.60News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$42.12-16.2%$1.48 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$24.52-4.4%$1.48 billion$175.34 million-14.42Analyst Report
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$26.06-4.4%$1.47 billionN/A0.00Insider Selling
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$35.96-15.6%$1.43 billionN/A-149.83News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.18-5.3%$1.43 billion$82.27 million-17.51
Kronos Bio logo
KRON
Kronos Bio
1.7$25.41-7.4%$1.42 billionN/A0.00Unusual Options Activity
Lockup Expiration
News Coverage
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.46-5.5%$1.42 billion$4.23 million-20.34
Endo International logo
ENDP
Endo International
1.3$6.17-0.5%$1.42 billion$2.91 billion-9.07News Coverage
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.36-2.9%$1.41 billion$19.89 million-13.38
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.